The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

This real-world study follows patients in China with early-stage non-small cell lung cancer (NSCLC) who receive immunotherapy before surgery (called neoadjuvant therapy). It observes how well this approach works in actual clinical practice outside of controlled trials. **You may be eligible if...** - You are 18 or older - You have been diagnosed with non-small cell lung cancer at stage II or IIIA that is potentially removable by surgery - Your cancer does not have EGFR or ALK mutations (specific genetic changes) - You are in good physical condition (ECOG score 0-1) - Your lung function is adequate for surgery **You may NOT be eligible if...** - Your cancer has the EGFR mutation or ALK rearrangement - Your cancer is at a stage that is not surgically removable - You are in poor physical condition Talk to your doctor to see if this trial is right for you.